Gastric Cancer Archives - Cancer Therapy Advisor

Gastric Cancer and the Link to Helicobacter Pylori Infection

ASCO 2021

Data Support Nivolumab Plus Chemo as Standard First-Line Therapy for Advanced Gastric, Esophageal Cancers

By

Mark L. Fuerst

June 6, 2021

Nivolumab plus chemotherapy improved overall survival.

Phase 3 RILOMET-1 study of rilotumumab for MET-positive gastric or gastroesophageal junction cancer

ASCO GI 2021

Trifluridine/Tipiracil Combination Effective in Third and Later-Line Metastatic Gastric Cancer

By

Leah Lawrence

January 22, 2021

This exploratory subgroup analysis of the TAGS study assessed the efficacy, safety, and quality of life (QOL) results observed in patients who received trifluridine/tipiracil or placebo in the third- or later-line settings.

Many changes occur in the GI tract during the aging process that can directly impact gastric motilit

ASCO GI 2021

Pembrolizumab Triplet Exhibits Efficacy in HER2-Positive Advanced Gastric, GEJ Cancer Independently of PD-L1 Status

By

Rachel Narozniak, MA

January 16, 2021

Investigators of the phase 1b/2 PANTHERA trial presented updated clinical and molecular profiling data from 43 patients who received frontline pembrolizumab, trastuzumab, and chemotherapy.

The diagnosis of linitis plastica, a subtype of gastric adenocarcinoma with a poor prognosis, can be

ESMO Virtual Congress 2020

First-Line Nivolumab Plus Chemotherapy Improves Survival in Gastric, Gastroesophageal Junction, and Esophageal Cancers

By

Andrea S. Blevins Primeau, PhD, MBA

September 21, 2020

Nivolumab plus chemotherapy prolonged survival of patients with advanced gastric, gastroesophageal junction, and esophageal cancers compared with chemotherapy.

The novel drug appeared effective in healthy, previously untreated patients, but cost, side effects, and other issues may stand in the way of its widespread use.

General Oncology

Analysis of Ramucirumab Suggests Risks Outweigh Benefits

By

Andrea S. Blevins Primeau, PhD, MBA

July 22, 2020

A meta-analysis of randomized controlled trials found that there are significant risks for severe or fatal adverse events with ramucirumab, with only modest improvements in OS or PFS.

ASCO 2020

Antibody-Drug Conjugate for Advanced HER2-Positive Gastric Cancer Improves Outcomes

By

Jody A. Charnow

May 30, 2020

T-DXd treatment was associated with a better ORR and prolonged OS compared with standard chemotherapy with either irinotecan or paclitaxel.

ASCO 2020

3 Years of Adjuvant Imatinib Improves Long-Term Overall Survival in Gastrointestinal Stromal Tumor

By

Andrea S. Blevins Primeau, PhD, MBA

May 29, 2020

Adjuvant treatment of GIST with imatinib for 36 months prolonged OS and RFS compared with 12 months of imatinib, according to data from nearly 10 years of follow-up.

Gastrointestinal Cancers

Weight Loss Following Chemotherapy Was Associated With Worse Outcomes in Patients With Advanced Gastric Cancer

By

Vicki Moore, PhD

May 29, 2020

These study findings show that weight loss occurred early among patients with advanced gastric cancer and was associated with shorter overall survival.